Novel radiotracer identifies biomarker for triple-negative breast cancer

Reston, VA (March 11, 2025)—A new PET radiotracer can effectively visualize Nectin-4, an emerging biomarker found in triple-negative breast cancer (TNBC). According to research published in the March issue of The Journal of Nuclear Medicine, the PET tracer has the potential to play a critical role in the diagnosis, treatment, and monitoring of this aggressive disease, improving clinical outcomes for patients.

TNBC accounts for 15-20 percent of breast cancer cases and is one of the most invasive subtypes, with a five-year survival rate of approximately 40 percent. As the disease is characterized by significant heterogeneity and a high rate of recurrence, treatment is often difficult.

“The Nectin-4 biomarker is highly expressed in TNBC, but effective, targeted imaging tools have been notably absent,” stated Shaoli Song, PhD, director of nuclear medicine in the Department of Nuclear Medicine at the Fudan University Shanghai Cancer Center in Shanghai, China. “To address this critical gap in the field, my colleagues and I developed a series of Nectin-4-targeted radiotracers and evaluated them for efficacy in detecting Nectin-4 in TNBC.”

Researchers developed three different Nectin-4-targeted radiotracers (⁶⁸Ga-FZ-NR-1, ⁶⁸Ga-FZ-NR-2, and ⁶⁸Ga-FZ-NR-3) and assessed their targeting-ability and specificity in vitro and in vivo, as well as in a murine tumor model. After preclinical experiments and screening, the ⁶⁸Ga-FZ-NR-1 radiotracer showed the highest targeting efficacy and was selected for evaluation in a first-in-human study. ⁶⁸Ga-FZ-NR-1 PET/CT was performed in nine TNBC patients. Positive lesions were biopsied and analyzed by immunohistochemistry to determine Nectin-4 expression levels.

⁶⁸Ga-FZ-NR-1 PET/CT effectively identified tumors in study participants, which was confirmed by ¹⁸F-FDG PET/CT. Biopsy samples of the tumor lesions revealed that the positive lesions identified by ⁶⁸Ga-FZ-NR-1 PET/CT corresponded to areas of high Nectin-4 expression. 

“The significance of this research lies in its potential to revolutionize the diagnostic landscape for TNBC patients,” said Song. “With the introduction of ⁶⁸Ga-FZ-NR-1, we are now able to detect tumors with greater precision and provide patients with more reliable diagnostic information. This advancement has the potential to improve treatment outcomes by enabling more accurate disease assessment and personalized therapeutic strategies.”

She continued, “We anticipate that this work will stimulate further research into the development and clinical application of Nectin-4-targeted imaging agents. Ultimately, this could enhance the diagnostic value of nuclear medicine not only for TNBC, but also for other cancers.”

The authors of “Pilot Study of Nectin-4–Targeted PET Imaging Agent ⁶⁸Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human” include Li Sun, Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China, Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, CAS Key Laboratory of Magnetic Materials and Devices, and Laboratory of Advanced Theranostic Materials and Technology, Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo, China, and Zhejiang International Cooperation Base of Biomedical Materials Technology and Application, Zhejiang Engineering Research Center for Biomedical Materials, Ningbo Cixi Institute of Biomedical Engineering, Cixi, China; Yuyun Sun, Jianping Zhang, Silong Hu, Xiaosheng Liu, Jindian Li, Ye Li, Xioping Xu, and Shaoli Song, Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China, and Center for Biomedical Imaging, Fudan University, Shanghai, China;Ke Zuo, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Lei Fan and Zhiming Shao, Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Xiao Wang, Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China; and Aiguo Wu, Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, CAS Key Laboratory of Magnetic Materials and Devices, and Laboratory of Advanced Theranostic Materials and Technology, Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo, China, and Zhejiang International Cooperation Base of Biomedical Materials Technology and Application, Zhejiang Engineering Research Center for Biomedical Materials, Ningbo Cixi Institute of Biomedical Engineering, Cixi, China.

 Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn.

###

Please visit the SNMMI Media Centerfor more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org.

About JNM and the Society of Nuclear Medicine and Molecular Imaging

 The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.

JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.